Compare GENC & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | SLP |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.2M | 250.6M |
| IPO Year | 1995 | 1996 |
| Metric | GENC | SLP |
|---|---|---|
| Price | $14.50 | $11.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $16.00 | ★ $25.00 |
| AVG Volume (30 Days) | 25.3K | ★ 203.3K |
| Earning Date | 02-06-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.23 | 0.03 |
| Revenue | $48,943,000.00 | ★ $59,577,000.00 |
| Revenue This Year | $6.36 | $2.64 |
| Revenue Next Year | $8.32 | $6.01 |
| P/E Ratio | ★ $61.43 | $387.65 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $10.80 | $11.16 |
| 52 Week High | $17.40 | $36.43 |
| Indicator | GENC | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 34.19 |
| Support Level | $13.56 | $11.16 |
| Resistance Level | $14.68 | $12.70 |
| Average True Range (ATR) | 0.54 | 0.50 |
| MACD | -0.19 | 0.16 |
| Stochastic Oscillator | 28.89 | 25.30 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.